Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC https://t.co/TMK99iKCfj

Clinical and molecular feature-based nomogram for predicting benefit from #bevacizumab combined with first-generation #TKI in #EGFR mutant advanced #NSCLC Read it here: https://t.co/Pa51JAwjpk https://t.co/pKY3CUNBiR

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC https://t.co/eSPC04KG0c

New article: Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC https://t.co/LKsTv3awGb #livercancer #oncology https: